Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CDC7 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDC7/DBF4 Co-expressed Complex / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CDC7 Products |
| Gene Delivery | CDC7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CDC7 Products |
| Benchmark Ab | Anti-CDC7 (Sequence of Reference Antibodies) Recombinant positive control. |
View CDC7 Products |
| Validator | CDC7 siRNA Set For knockdown verification. |
View CDC7 Products |
| Related Target A | DBF4 Essential regulatory subunit forming the active DDK kinase complex with CDC7. |
View DBF4 Products |
| Related Target B | CDK2 Key homologous kinase for selectivity counter-screening. |
View CDK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Active Kinase Complex Assembly | Co-expressed CDC7/DBF4 complex with verified theoretical MW and >95% purity |
| Kinase Selectivity Counter-screening | Broad panel of homologous CDK family proteins strictly verified by mass spec |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CDC7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDC7 therapeutics is heavily focused on small molecule kinase inhibitors, driven by the target's critical role in DNA replication initiation (DDK complex). As first-generation therapies navigate clinical trials, the next wave of R&D is targeting synthetic lethality combinations, particularly pairing CDC7 inhibitors with PARP inhibitors or ATR/ATM modulators in p53-mutated solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Takeda, Eli Lilly, Nerviano | Solid Tumors, AML | Selectivity Assay (Need High-Purity Co-expressed CDC7/DBF4) |
| Targeted Degradation (PROTAC) | Emerging Biotechs | Refractory Cancers | Ternary Complex Validation (Need Sequence Verified Proteins) |